Pharma BD Deal Intelligence
Headline frames the deal as putting 'Roche back in the sequencing game,' positioning Genia's single-molecule nanopore platform as Roche's vehicle to re-enter…
Roche acquired Genia Technologies for $125M upfront plus up to $225M in milestones, gaining a single-molecule nanopore platform after the failed Illumina bid…
Roche plans a 2026 launch for its SBX nanopore platform — built on Genia's 2014-acquired semiconductor chip plus Stratos Genomics' SBX chemistry — claiming…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Roche acquired Mountain View-based Genia Technologies for $125M upfront plus up to $225M in milestones, gaining a single-molecule nanopore sequencing platform after Roche's earlier failed PacBio deal. The deal positioned Roche to compete in clinical NGS against Illumina and Thermo.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Genia Technologies, Inc. (this deal) | 2014 | $350M | 74 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2014 deals · Roche Holding AG deals · Other deals